Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial.

ABSTRACT:

Background

The mammalian target of rapamycin (mTOR) inhibitor everolimus is used in the treatment of breast cancer, neuroendocrine tumors, and renal cancer. The approved 10 mg once-daily dose is associated with considerable adverse effects and it has been suggested that these are associated with the maximum concentration (C _max) of everolimus. Twice-daily dosing might be an alternative strategy with improved tolerability; however, a direct pharmacokinetic comparison of 10 mg once-daily with 5 mg twice-daily dosing is lacking.

Methods

We performed a prospective, randomized, pharmacokinetic, crossover trial comparing everolimus 10 mg once daily with 5 mg twice daily. Patients received the first dose schedule for 2 weeks and then switched to the alternative regimen f

SUBMITTER: Verheijen RB 

PROVIDER: S-EPMC5904242 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature